Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials

References

• Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35:3484–3515.
   PubMed Web of Science ®Google Scholar
• Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v1–v27.
   PubMed Web of Science ®Google Scholar
• Iyer S, Roughley A, Rider A, et al. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study. Support Care Cancer. 2014;22:181–187.
   PubMed Web of Science ®Google Scholar
• Sung MR, Patel MV, Djalalov S, et al. Evolution of symptom burden of advanced lung cancer over a decade. Clin Lung Cancer. 2017;18:274–280.e6.
   PubMed Web of Science ®Google Scholar
• Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. JCO. 2004;22:3485–3490.
   PubMed Web of Science ®Google Scholar
• Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer. 2011;19:1421–1427.
   PubMed Web of Science ®Google Scholar
• Fortner BV, Houts AC, Schwartzberg LS. A prospective investigation of chemotherapy-induced neutropenia and quality of life. J Support Oncol. 2006;4:472–478.
   PubMedGoogle Scholar
• Fortner BV, Schwartzberg L, Tauer K, et al. Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. Support Care Cancer. 2005;13:522–528.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hozaeel W, Tauchert FK, et al. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol. 2015;26:1244–1248.
   PubMed Web of Science ®Google Scholar
• Flotten O, Gronberg BH, Bremnes R, et al. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012;107:442–447.
   PubMed Web of Science ®Google Scholar
• Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. JCO. 2009;27:3217–3224.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376.
   PubMed Web of Science ®Google Scholar
• Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer (Oxford, England: 1990). 1994;30: 635–642.
   Web of Science ®Google Scholar
• Feyer P, Kleeberg UR, Steingraber M, et al. Frequency of side effects in outpatient cancer care and their influence on patient satisfaction – a prospective survey using the PASQOC questionnaire. Support Care Cancer. 2008;16:567–575.
   PubMed Web of Science ®Google Scholar
• Fayers PM, Aaronson N, Bjordal K. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels, Belgium: European Organisation for Research and Treatment of Cancer; 2001.
   Google Scholar
• Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. JCO. 1998;16:139–144.
   PubMed Web of Science ®Google Scholar
• Maringwa JT, Quinten C, King M, et al. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support Care Cancer. 2011;19:1753–1760.
   PubMed Web of Science ®Google Scholar
• Kristensen A, Solheim TS, Amundsen T, et al. Measurement of health-related quality of life during chemotherapy – the importance of timing. Acta Oncol (Stockholm, Sweden). 2017;56:737–745.
   PubMed Web of Science ®Google Scholar
• Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005;6:669–677.
   PubMed Web of Science ®Google Scholar
• Pallis AG, Agelaki S, Kakolyris S, et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Lung Cancer (Amsterdam, Netherlands). 2008;62:356–363.
   PubMed Web of Science ®Google Scholar
• Rambach L, Bertaut A, Vincent J, et al. Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients. WJG. 2014;20:1565–1573.
   PubMed Web of Science ®Google Scholar